Nkarta, Inc..
NKTX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Nkarta, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel cell therapies to treat cancer. The company engineers natural killer (NK) cells to target and kill cancer cells. Their primary focus is on developing off-the-shelf, allogeneic NK cell therapies,...Show More
Better Health for All
40
Nkarta's core business is entirely devoted to health improvement, developing allogeneic, off-the-shelf natural killer (NK) cell therapies to treat serious conditions like autoimmune diseases and advanced blood cancers.
1
These therapies aim to transform the standard of care and deliver exceptional health benefits, with early clinical trial results showing complete remissions in 3 out of 5 patients with acute myeloid leukemia and 3 out of 6 patients with advanced lymphomas.
2
For safety, preliminary Phase 1 clinical trial data reported no cases of cytokine release syndrome, immune cell-associated neurotoxicity syndrome, or graft-versus-host disease higher than Grade 3.
3
The company aims to make cell therapy broadly available by pioneering allogeneic NK cells that can be dosed in outpatient, community health settings, without complicated logistics or lengthy safety monitoring.
4
Nkarta focuses on B cell-mediated autoimmune diseases, which affect 7 million people in the United States.
5
As a clinical-stage biotechnology company, its entire R&D budget is dedicated to advancing these therapies, combining cell expansion, cryopreservation, and proprietary cell engineering technologies.
6
Nkarta held a 2026 Investigator Meeting with clinical investigators and study teams from trial sites across the country, demonstrating support for the healthcare workforce.
7
The company strives to design research around the lives of patients to make clinical trial opportunities more accessible and equitable, with trial information available on ClinicalTrials.gov.
8
Fair Money & Economic Opportunity
0
No evidence available to assess Nkarta, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
Nkarta underwent significant workforce reductions, laying off 34% of its employees, which amounted to 53 positions, in March 2025.
1
This restructuring also impacted more than half of the executive leadership team.
2
The company had previously laid off approximately 10% of its staff in October 2023.
3
Nkarta anticipates incurring $5.5 million to $6.5 million in costs related to the March 2025 layoffs.
4
As of December 31, the company reported having 157 full-time employees.
5
The CEO stated the restructuring "impacts every level of the organization."
6
Fair Trade & Ethical Sourcing
0
No quantitative data or specific information regarding Nkarta, Inc.'s fair trade and ethical sourcing practices, including fair-trade certification share, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend, was found in the provided articles.
1
Honest & Fair Business
0
No specific, concrete data points relevant to the 'Honest & Fair Business' KPIs were found in the provided article.
1
The article indicated that content retrieval was throttled, resulting in no available information for assessment.
2
Kind to Animals
0
No evidence available to assess Nkarta, Inc. on Kind to Animals.
No War, No Weapons
0
The provided articles focus on Nkarta, Inc.'s biopharmaceutical activities
1
and investor conferences.
2
They do not contain any specific, concrete data points or information regarding the company's involvement with arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding initiatives, or any other activities relevant to the 'No War, No Weapons' ethical value.
3
Consequently, no KPIs can be scored based on the evidence provided.
Planet-Friendly Business
0
The provided articles for Nkarta, Inc. do not contain any specific environmental data or information relevant to the Planet-Friendly Business KPIs, such as greenhouse gas emissions, renewable energy use, water consumption, waste diversion, or climate targets.
1
One article focuses on the company's pipeline of NK cell therapies,
2
while the other discusses a different company, CRISPR Therapeutics.
3
Respect for Cultures & Communities
0
No specific, quantifiable evidence was found in the provided articles to assess Nkarta, Inc. against any of the KPIs for 'Respect for Cultures & Communities'. The articles either explicitly state 'No data provided' for Nkarta, Inc. regarding these metrics, or discuss general industry trends without company-specific data.
1
While one article mentions a donation of toys, books, and furniture to a residential treatment program,
2
this information is not quantifiable as a percentage of revenue, nor does it specify the recipient as a cultural heritage organization, which is required for scoring relevant KPIs.
Safe & Smart Tech
-30
Nkarta, Inc. reports no material cyber incidents affecting its business or financial condition, and has an Incident Response Plan (IRP) and Incident Response Team (IRT) in place.
1
No specific incidents of unauthorized data use are detailed.
2
The company's Privacy Policy, last updated December 9, 2024, outlines user choices to decline sharing information, update, correct, or delete account information, access and amend personal information via email, and manage promotional communications.
3
However, the policy states the site is hosted in the US and intended for US visitors, with data transferred from outside the EU/other regions to the US for storage and processing, without mentioning specific compliance with international regulations like GDPR or CCPA.
4
Zero Waste & Sustainable Products
0
No evidence available to assess Nkarta, Inc. on Zero Waste & Sustainable Products.